Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Best Longevity Stocks to Buy Now .

On June 7, 2026, Amgen Inc. (NASDAQ:AMGN) announced new data at the American Diabetes Association 86th Scientific Sessions, including Phase 3 VESALIUS-CV subgroup results for Repatha in patients with high-risk diabetes and elevated LDL-C without prior heart attack or stroke. In an analysis of 6,002 patients, Repatha, when added to statins or other LDL-C-lowering therapies, reduced the risk of the composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% compared with placebo. Repatha also reduced the risk of a second composite primary endpoint that included ischemia-driven revascularization by 21%.

On June 5, 2026, Goldman Sachs lowered the firm's price target on Amgen Inc. (NASDAQ:AMGN) to $389 from $425 and maintained a Buy rating on the shares. Goldman Sachs adjusted its model after Amgen disclosed in its Q1 earnings that the IRS audit for 2016 to 2018 had escalated into a formal dispute, with the company receiving a notice of proposed adjustment.

Earlier in June, Amgen announced that the European Commission granted marketing authorization for Imdylltra as a monotherapy for adults with extensive-stage small cell lung cancer who require systemic therapy after disease progression on or after first-line platinum-based chemotherapy.

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .